Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7810457> ?p ?o }
Showing triples 1 to 33 of
33
with 100 triples per page.
- Q7810457 subject Q6870315.
- Q7810457 subject Q7116685.
- Q7810457 subject Q8252271.
- Q7810457 subject Q8431759.
- Q7810457 subject Q8636858.
- Q7810457 abstract "Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor. It is undergoing clinical trial investigation for the treatment of renal cell carcinomas. An oral quinoline urea derivative, tivozanib suppresses angiogenesis by being selectively inhibitory against vascular endothelial growth factor. It was developed by AVEO Pharmaceuticals. It is designed to inhibit all three VEGF receptors.Phase III results on advanced renal cell carcinoma suggest a 30% or 3 months improvement in median PFS compared to sorafenib. The Food and Drug Administration's Oncologic Drugs Advisory Committee voted in May 2013 13 to 1 against recommending approval of tivozanib for renal cell carcinoma. The committee felt the drug failed to show a favorable risk-benefit ratio and questioned the equipose of the trial design, which allowed control arm patients who used sorafenib to transition to tivozanib following progression disease but not those on the experimental arm using tivozanib to transition to sorafenib. There was an inferior overall survival rate of the experimental arm versus the control arm in this Phase III study as well. The application was formally rejected by the FDA in June 2013, saying that approval would require additional clinical studies.".
- Q7810457 iupacName "1-{2-Chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methylisoxazol-3-yl)urea".
- Q7810457 thumbnail Tivozanib.svg?width=300.
- Q7810457 wikiPageWikiLink Q1164529.
- Q7810457 wikiPageWikiLink Q1368197.
- Q7810457 wikiPageWikiLink Q204711.
- Q7810457 wikiPageWikiLink Q2112244.
- Q7810457 wikiPageWikiLink Q29725.
- Q7810457 wikiPageWikiLink Q309510.
- Q7810457 wikiPageWikiLink Q408384.
- Q7810457 wikiPageWikiLink Q421136.
- Q7810457 wikiPageWikiLink Q4356503.
- Q7810457 wikiPageWikiLink Q48318.
- Q7810457 wikiPageWikiLink Q539568.
- Q7810457 wikiPageWikiLink Q6870315.
- Q7810457 wikiPageWikiLink Q7116685.
- Q7810457 wikiPageWikiLink Q8252271.
- Q7810457 wikiPageWikiLink Q8431759.
- Q7810457 wikiPageWikiLink Q8636858.
- Q7810457 iupacname "1".
- Q7810457 type ChemicalCompound.
- Q7810457 type ChemicalSubstance.
- Q7810457 type ChemicalObject.
- Q7810457 type Thing.
- Q7810457 type Q11173.
- Q7810457 comment "Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor. It is undergoing clinical trial investigation for the treatment of renal cell carcinomas. An oral quinoline urea derivative, tivozanib suppresses angiogenesis by being selectively inhibitory against vascular endothelial growth factor. It was developed by AVEO Pharmaceuticals.".
- Q7810457 label "Tivozanib".
- Q7810457 depiction Tivozanib.svg.